Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (81-90 of 802) with videos related to

Pageof 81
Sort By:
Pulmonary Pharmacology & Therapeutics|April 13, 2010
The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDMario Cazzola, Mathieu Molimard
BMJ Evidence-Based Medicine|June 29, 2018
Tiotropium could provide benefits in the early stage of COPD, but further studies are neededMario Cazzola, Paola Rogliani
Hematology. American Society of Hematology. Education Program|December 6, 2015
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)Luca Malcovati, Mario Cazzola
Evidence-Based Medicine|August 13, 2017
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV <sub></sub> than long-acting beta-agonists plus inhaled corticosteroidsMario Cazzola, Paola Rogliani
Respiration; International Review of Thoracic Diseases|January 17, 2021
Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent ExacerbatorsMario Cazzola, Bartolome Celli
The European Respiratory Journal|April 4, 2014
Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary diseaseClive Page, Mario Cazzola
Blood|May 3, 2014
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasmsMario Cazzola, Robert Kralovics
Haematologica|October 24, 2024
Genome sequencing in the management of myelodysplastic syndromes and related disordersMario Cazzola, Luca Malcovati
Blood|January 9, 2025
How I manage patients with unexplained cytopeniaLuca Malcovati, Mario Cazzola
Expert Opinion on Pharmacotherapy|October 21, 2014
Triple combinations in chronic obstructive pulmonary disease - is three better than two?Mario Cazzola, Maria Gabriella Matera
Pageof 81

Showing results (81-90 of 802) with videos related to

Sort By:
Pageof 81
Pulmonary Pharmacology & Therapeutics|April 13, 2010
The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDMario Cazzola, Mathieu Molimard
BMJ Evidence-Based Medicine|June 29, 2018
Tiotropium could provide benefits in the early stage of COPD, but further studies are neededMario Cazzola, Paola Rogliani
Hematology. American Society of Hematology. Education Program|December 6, 2015
The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)Luca Malcovati, Mario Cazzola
Evidence-Based Medicine|August 13, 2017
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV <sub></sub> than long-acting beta-agonists plus inhaled corticosteroidsMario Cazzola, Paola Rogliani
Respiration; International Review of Thoracic Diseases|January 17, 2021
Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent ExacerbatorsMario Cazzola, Bartolome Celli
The European Respiratory Journal|April 4, 2014
Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary diseaseClive Page, Mario Cazzola
Blood|May 3, 2014
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasmsMario Cazzola, Robert Kralovics
Haematologica|October 24, 2024
Genome sequencing in the management of myelodysplastic syndromes and related disordersMario Cazzola, Luca Malcovati
Blood|January 9, 2025
How I manage patients with unexplained cytopeniaLuca Malcovati, Mario Cazzola
Expert Opinion on Pharmacotherapy|October 21, 2014
Triple combinations in chronic obstructive pulmonary disease - is three better than two?Mario Cazzola, Maria Gabriella Matera
Pageof 81